Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution, PK and Safety of [89Zr]Zr-DFO-AP-101 PET in Healthy Volunteers and ALS Patients
NCT05974579Phase 1Completed
- Sponsor
- Université de Sherbrooke
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of 89Zr-DFO-AP-101 in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Université de Sherbrooke. Primary endpoints: Incidence of adverse events (AEs) and serious adverse events (SAEs), Biodistribution of [89Zr]Zr-DFO-AP-101 at 10 days and 1 more. Started Nov 2023; status: completed.
02
Drugs
89Zr-DFO-AP-101
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05974579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05974579.